Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Osivax
Pioneering A New Class of Universal Vaccines
Biotechnology Research Lyon, Auvergne-Rhône-Alpes
Osivax’ mission is to develop “universal” vaccines against highly-mutating viruses. Leveraging its unique oligoDOM® technology platform, OSIVAX is developing a universal vaccine for both current and future influenza infections. The Company’s universal flu vaccine candidate, OVX836 is in Phase 2a clinical development. OSIVAX is leveraging the same platform technology for the development of a universal vaccine against all existing and emerging coronavirus infections. OSIVAX is focused on providing proof-of-concept in influenza and coronavirus, and to applying its oligoDOM® platform broadly in other infectious and immune system-associated diseases.
www.researchgate.net › publication › 6961040Strategy for determination of an efficient Cochleate particle ...
OSIVAX; Show all 8 authors Hide. Request full-text PDF. To read the full-text of this research, you can request a copy directly from the authors. ... virosomes, nano- and microparticulate systems ...
www.researchgate.net › publication › 343739139(PDF) Repurposing Drugs, Ongoing Vaccine, and ... - ResearchGate
105 Preclinical VLP vaccine protein-based vaccine Osivax, France. 106 Preclinical COVID-19 vaccine whole inactivated virus-based. vaccine. Panacea Biotec Ltd., India.
www.researchgate.net › publication › 6796339Economic and practical challenges to the ... - ResearchGate
Gerald Voss; Joe Cohen; ... When delivered to the immune system on human-compatible virus like particles (virosomes), the mimetic effectively elicits sporozoite-binding antibodies. This virosome ...
pubmed.ncbi.nlm.nih.gov › 21208909An adjuvanted polyprotein HIV-1 vaccine induces ...
Eva Van Braeckel 1 , Patricia Bourguignon, Marguerite Koutsoukos, Frédéric Clement, Michel Janssens, Isabelle Carletti, Alix Collard, Marie-Ange Demoitié, Gerald Voss, Geert Leroux-Roels, Lisa McNally
Author: Eva Van Braeckel, Patricia Bourguignon, Marguerite Koutsoukos, Frédéric Clement, Michel Janssens, Is...
Publish Year: 2011
Why is Vaginal Study not on the NIH Website?
Thank you, Corpus, What do you think Big Bonanza coming?
ON WITH THE SHOW THIS IS IT
www.mdpi.com › 1999/4923/14-3 › 621Pharmaceutics | Free Full-Text | LncRNA: A Potential Target ...
Pharmaceutics 2022, 14(3), 621; ... 9 March 2022 / Published: 11 March 2022 ... A virosomal vaccine against candidal vaginitis: Immunogenicity, efficacy and safety ...
https://www.mdpi.com/1999-4923/14/3/621/htm
EU Official Control Authority Batch Release
Human Vaccines
Guideline for
Influenza Vaccine (Surface Antigen, Inactivated, Virosome)
This version in force from 01/07/2020
Replacing version in force from 01/01/2019
https://view.officeapps.live.com/op/view.aspx?src=https%3A%2F%2Fwww.edqm.eu%2Fsites%2Fdefault%2Ffiles%2F39_influenzaviro_150620.doc&wdOrigin=BROWSELINK
www.medscape.org › viewarticle › 727478Test Your Adjuvant IQ: Ten Things You Need to Know ... - Medscape
Mar 20, 2022 · Sunday, March 20, 2022. ... and the virosomal-adjuvanted vaccine is approved for use in children and adults in Europe.
A SARS-CoV-2 Wuhan spike virosome vaccine induces superior neutralization breadth compared to one using the Beta spike
Yme U. van der Velden, Marloes Grobben, Tom G. Caniels, Judith A. Burger, Meliawati Poniman, Melissa Oomen, Esther Siteur-van Rijnstra, Khadija Tejjani, Denise Guerra, Ronald Kempers, Toon Stegmann, Marit J. van Gils & Rogier W. Sanders
Our results show that Beta spike vaccination induces inferior neutralization breadth. These results are informative for programs aimed to develop broadly active SARS-CoV-2 vaccines.
Hey! Dr. Ronald Kempers!!!
https://www.nature.com/articles/s41598-022-07590-w
patents.justia.com › patent › 9402893Liposome-peptide conjugate and method of using same ... - Justia
Apr 13, 2007 · Zwick, M. B., et al., 2004, The long third complementarity-determining region of the heavy chain is important in the activity of the broadly neutralizing anti-human immunodeficiency
[img][/img]Liposome-peptide conjugate and method of using same to induce production of anti-HIV antibodies
Apr 13, 2007 - DUKE UNIVERSITY
The present invention relates to a method of inducing the production of anti-HIV antibodies. The method comprises administering at least one liposome-peptide conjugate, wherein the peptide comprises a membrane proximal external region (MPER) epitope.
https://patents.justia.com/patent/9402893
https://www.scripps.edu/faculty/zwick/
dhvi.duke.edu › our-programs › hiv-vaccine-researchHIV Vaccine Research and Development (HIVRAD) | Duke Human ...
The Duke Human Vaccine Institute houses three NIAID funded HIV Vaccine Research and Development (HIVRAD) programs. 1. Immunogen Design for Induction of HIV Distal gp41 Broadly
https://dhvi.duke.edu/our-programs/hiv-vaccine-research-and-development-hivrad
Hey Corpus, Where's the big BONANZA"""""""
The COVID-19 pandemic caused by SARS-CoV-2 seriously threatens global public health. It has previously been confirmed that SARS-CoV-2 is mainly transmitted between people through “respiratory droplets”. Therefore, the respiratory tract mucosa is the first barrier to prevent virus invasion. It is very important to stimulate mucosal immunity to protect the body from respiratory virus infection. Inspired by this, we designed a bionic-virus nanovaccine, which can induce mucosal immunity by nasal delivery to prevent virus infection from respiratory tract. The nanovaccine that mimic virosome is composed of poly(I:C) mimicking viral genetic material as immune adjuvant, biomimetic pulmonary surfactant (bio-PS) liposomes as capsid structure of virus and the receptor binding domains (RBDs) of SARS-CoV-2 as “spike” to completely simulate the structure of the coronavirus. The nanovaccine can be administered by inhaling to imitate the process of SARS-CoV-2 infection through the respiratory tract. Our results demonstrated that the inhalable nanovaccine with bionic virus-like structure has a stronger mucosal protective effect than routine muscle and subcutaneous inoculation. In particular, high titer of secretory immunoglobulin A (sIgA) was detected in respiratory secretions, which effectively neutralize the virus and prevent it from entering the body through the respiratory tract. Through imitating the structure and route of infection, this inhalable nanovaccine strategy might inspire a new approach to the precaution of respiratory viruses.
School of Life Sciences, Tianjin University, 92 Weijin Road, Nankai District, Tianjin 300072, PR China
https://www.sciencedirect.com/science/article/pii/S1385894721009803?via%3Dihub#!
Core Outcomes Set for Trials in People With Coronavirus ...
30 Section of Infectious Diseases Department of Medicine, National School of Tropical Medicine, Baylor College of Medicine, Houston, TX. 31 Evidence-based Medicine center, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Author: Allison Tong, Julian H. Elliott, Luciano Cesar Azevedo, Amanda Baumgart, Andrew Bersten, Lilia Cerva...
Publish Year: 2020
rGP41 (HIV-1)
Gp41 also known as glycoprotein 41 is a subunit of the envelope protein complex of retroviruses, including Human immunodeficiency virus (HIV). Gp41 is a transmembrane protein that contains several sites within its ectodomain that are required for infection of host cells. The env gene codes for gp160, a precursor, which is extensively glycosylated and proteolytically cleaved into two subunits gp120 and gp41 (this protein) by furin, a host cellular protease.
http://span-diagnostics.com/product/rgp41-hiv-1/
rgp41 (HIV-1)
http://span-diagnostics.com/wp-content/uploads/2019/10/rGP41-1.pdf
Mario Amacker
Scientific Advisory Board
Nesher Pharmaceuticals Inc
Romania
Biography
Previous roles include Head of Process Development and Head of Technology for virosomal vaccines at Pevion Biotech. Dr. Amacker holds a Ph.D. in veterinary biochemistry from the University of Zurich, Switzerland. More than 10 years of hands-on experience in process development, manufacturing and quality control, project management, and quality assurance in small biotech corporate setting.
Research Interest
Biochemistry
https://biography.omicsonline.org/romania/nesher-pharmaceuticals-inc/mario-amacker-1230891
LMAO!!!!!!!!!!! ;)
6.3.3 Vaginal route
Vaginal administration was selected based on recommendations from experts gathered at the beginning of the project: best vaginal responses are elicited after vaginal immunization. Three vaginal priming with URG7-A and CT in drops induced IgG – not IgA - responses in serum. As with the nasal route, the neutralising activity induced with drops was poor.
Three vaginal primes and 2 vaginal boosts with UGR7 in gel elicited serum IgG, mucosal IgG and IgA and responses were higher when the protein was administered in the presence of CT adjuvant. HIV inhibitory responses were modest in serum and lavages after 3 primes and were not improved by 2 vaginal boosts. This activity was increased when UGR7 was combined with CT. Comparing with the previous study, the gel may show an advantage over the drops for immunogenicity.
To further improve Ag retention on the mucosa, freeze-dried solid formulations were prepared. Vaginal priming with sustained-release rod containing UGR7 induced a serum IgG response in the absence of adjuvant. Mucosal IgA were reliably detected in Weck-cels in the absence of a mucosal IgG response. UGR7 vaginal rods also induced a neutralizing response in serum which was improved by higher dose of UGR7. HIV inhibitory activity was also detected in the vaginal lavages. However, placebo rods alone induced an HIV-inhibitory activity, probably by inflammation of the vagina with release of chemokine/cytokine able to neutralise the virus. It was therefore difficult to distinguish the contribution of the induced immune response in the neutralisation of the virus.
Nasal and vaginal routes were also used with other Ags presented in liposomes and MPLA (Harvard 5D1C, MPEX-16 and Harvard 5B). No responses were observed in serum or mucosa after administration whereas good specific IgG responses were elicited in serum by all immunogens after IM injections. Interestingly, after mucosal priming followed by IM boosts, responses in Weck cels were restricted to IgA but they were borne by IgG and IgA after IM injections in the absence of mucosal prime.
6.3.4 Conclusions
The SL route was not potent in eliciting an immune response but both nasal and vaginal routes proved to be efficient. The restricted IgA profile of the response at the mucosal level, as opposed to the IgG/IgA after IM route only is an example of the qualitative modulation of the immune response by mucosal application. In serum, most of the responses to all antigens were IgG rather than IgA, whatever the route of administration.
https://cordis.europa.eu/project/id/201038/reporting
YOU KNOW THAT PX THERAPEUTICS USING RGP41 IN THERE HIV TRAIL?
PX’Therapeutics Announces EuroNeut-41 Prophylactic HIV Vaccine Clinical Trial
Published: Mar 13, 2012
GRENOBLE, France--(BUSINESS WIRE)--PX’Therapeutics is pleased to announce the launching of a Phase 1 clinical trial of a prophylactic vaccine against HIV entitled: “Phase 1, Randomised, Single-centre, Observer-blind Clinical Trial of Safety and Immunogenicity of Nasal-prime and Intramuscular Boost Immunisation With EN41-FPA2 HIV Vaccine in Healthy Female Volunteers.”
https://www.biospace.com/article/releases/px-therapeutics-announces-euroneut-41-prophylactic-hiv-vaccine-clinical-trial-/
PX’THERAPEUTICS ANNOUNCES THE SUCCESSFUL COMPLETION OF RGP41 GMP MANUFACTURING FOR MYMETICS
https://lyonbiopole.com/en/actualites/pxtherapeutics-annonce-reussite-de-production-dun-lot-clinique-de-rgp41-mymetics
The Cancer Consortium
CANCER NEWS & INFORMATION CENTER
SATURDAY, MARCH 5TH, 2022
BLOG
Clinical Trial of GeoVax’s AIDS Vaccine Moves Forward
BY GLOBAL CANCER CONSORTIUM ON JULY 5, 2010
A year ago, we reported on the push to discover an effective AIDS vaccine. As President Obama prepares to release his U.S. AIDS strategy, at least one pharmaceutical company is readying a crucial clinical trial of its vaccine against HIV/AIDS.
Mymetics Corporation is currently testing the first human volunteers in a clinical trial of its preventive AIDS vaccine. The vaccine was well-tolerated by participants. The new study follows an animal trial in which the vaccine demonstrated the ability to prevent infection with the HIV virus. Participants in the human study will be followed for 12 months. The CDC estimates that 1.2 million people in the U.S. have HIV, the virus that causes AIDS.
https://www.thecancerconsortium.org/2010/07/clinical-trial-of-geovaxs-aids-vaccine-moves-forward/
RONALD KEMPERS
President, Chief Executive Officer and Chief Financial Officer
Joined Mymetics in July 2009 as Chief Operating Officer and was appointed President and CEO of Mymetics Corporation in November 2012 while assuming as well the function of Chief Financial Officer.
https://www.mymetics.com/about/ronald-kempers/
This article was in April 1, 2011
The vaccine world has viewed Mymetics’ mucosal approach with skepticism. However, “when the macaque results were made public, it became difficult to ignore that our approach is valid,” says Ronald Kempers, CFO. The Gates Foundation, National Institutes of Health and other international agencies are watching the progress of the Mymetics platform.
https://www.genengnews.com/magazine/155/targeting-viruses-before-they-enter-the-body/
Conducted at the Center for Vaccinology at the University of Ghent, Belgium, the women received two injections of the vaccine, followed by two doses given as a nasal spray. The preliminary results in macaques and humans “are an important validation of our work and approach.”
The vaccine world has viewed Mymetics’ mucosal approach with skepticism. However, “when the macaque results were made public, it became difficult to ignore that our approach is valid,” says Ronald Kempers, CFO. The Gates Foundation, National Institutes of Health and other international agencies are watching the progress of the Mymetics platform.
https://www.genengnews.com/magazine/155/targeting-viruses-before-they-enter-the-body/
Virosome Projects NIH
Look at these: Projects
Publications
Patents
Clinical Studies
News & More
https://reporter.nih.gov/search/cKx7iWDpXkmi4cCby1hSAw/projects
from last post GSK LMAO
inventor/designer: BETH-ANN COLLER VERONIQUE HENDERICKX NATHALIE MARIE-JOSEPHE GARCON
BETH ANN COLLER
www.linkedin.com › in › beth-ann-coller-2775097Beth-Ann Coller - Executive Director, Global Clinical ...
Beth-Ann Coller - Executive Director, Global Clinical Development - Vaccines - Merck & Co. | LinkedIn Beth-Ann Coller Merck and Co. West Point, Pennsylvania, United States500+ connections Join to...
Location: West Point, Pennsylvania, United States
Works For: Merck & Co.
Occupation: Merck And Co.
patents.google.com › patent › EP2269638A3EP2269638A3 - Vaccine compositions comprising virosomes and a ...
Beth-Ann Coller Veronique Henderickx Nathalie M J Garcon Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.) GlaxoSmithKline Biologicals SA Original Assignee GlaxoSmithKline Biologicals SA
Author: Beth-Ann GlaxoSmithKline Bio. S.A. Coller, Véronique GlaxoSmithKline Bio. S.A. Henderickx, Nathalie ...
Publish Year: 2005
VERONIQUE HENDERICKX
be.linkedin.com › in › véronique-henderickx-bb4392118Véronique Henderickx - Senior manager - GSK | LinkedIn
View Véronique Henderickx’s profile on LinkedIn, the world’s largest professional community. Véronique has 1 job listed on their profile. See the complete profile on LinkedIn and discover Véronique’s connections and jobs at similar companies.
Location: Rixensart, Walloon Region, Belgium
NATHALIE GARCON
August 1990 - July 2014
GlaxoSmithKline
London, United Kingdom
Position
VP, head adjuvant and technology innovation center
This goes way back that University of Berns Know!!!
Oncology Hoffmann-LaRoche!!!
Original Article
Published: 05 June 2004
Virosomes as new carrier system for cancer vaccines
Claude D. Gimmi
Department of Clinical Research, University of Bern, Bern, Switzerland
Global Drug Development, Oncology, F. Hoffmann-LaRoche, PDM2, Grenzacherstrasse, 4070, Basel, Switzerland
Dominique Mueller
Institute of Pathology, University of Bern, Bern, Switzerland
Antoinette Wetterwald,
Institute of Pathology, University of Bern, Bern, Switzerland
Ernst Waelti,
Institute of Pathology, University of Bern, Bern, Switzerland
Ruth Schwaninger
Department of Clinical Research, University of Bern, Bern, Switzerland
https://link.springer.com/article/10.1007/s00262-004-0545-5
https://www.researchgate.net/publication/8522098_Virosomes_as_new_carrier_system_for_cancer_vaccines
GSK LMAO
Vaccine compositions comprising virosomes and a saponin adjuvant
[Patent]. AU2005249212(B2) GLAXOSMITHKLINE BIOLOGICALS S.A. 2010-05-20
?abstract? ... compositions containing said virosome preparations, methods of preparing said virosome preparations and vaccine containing them.
home>patent>Vaccine compositions comprising virosomes and a saponin adjuvant
Vaccine compositions comprising virosomes and a saponin adjuvant
export collection share error correcting
summary:
The invention provides virosome preparations from an enveloped virus, in particular from influenza virus, containing an antigen from said virus, and a saponin adjuvant. In particular the invention provides a virosome preparation from influenza virus containing an influenza antigen a QS21, optionally with a sterol. The invention also provides vaccine compositions containing said virosome preparations, methods of preparing said virosome preparations and vaccine containing them.
application/patent no.:AU2005249212(B2)
application date:2005-05-26
publication/announcement number:AU2005249212(B2)
disclosure/announcement date:2010-05-20
primary class number:A61K9/127 A A61 A61K A61K9
classification number:A61K9/127 A61K9/50 A61K39/145 A61K39/39 A61K47/46 A61K47/48
applicant/patentee:GLAXOSMITHKLINE BIOLOGICALS S.A.
inventor/designer:BETH-ANN COLLER VERONIQUE HENDERICKX NATHALIE MARIE-JOSEPHE GARCON
Table 2 - uploaded by Mario Amacker
https://www.researchgate.net/figure/Virosome-based-vaccines-in-clinical-development_tbl2_51064197
Team ? UPDEPALMA - EPFL
https://www.epfl.ch/labs/depalma-lab/team/
... he joined the Pasteur Institute of Tehran as a full-time research associate, where they developed a DNA delivery platform based on Virosome technology.
https://search.epfl.ch/?q=virosome%202022
Yahya Mohammadzadeh
PhD student +41(0)2169 37293
SV2528
Yahya Mohammadzadeh obtained his bachelor in Cell and Molecular Biology in 2015 from the Ferdowsi University of Mashhad (FUM) in Iran. During his undergraduate study, he joined the Pasteur Institute of Tehran as a full-time research associate, where they developed a DNA delivery platform based on Virosome technology. He then moved to the University of British Columbia (UBC), Canada, to pursue his master study. During the course of his master, he studied the process of mitophagy (autophagy of damaged mitochondria). After graduating from UBC in 2018, he joined the De Palma’s lab at EPFL to develop the EVIR-DC platform.
Erwann Loret obtained is Ph. D. in France in February 1990, then he went to USA for a first post-doc in the department of biophysics and biochemistry at Oregon State University, followed by a second post-doc in the department of chemistry at the University of California, Davis. He was hired in 1992 in the Centre National de Recherche Scientifique(CNRS), which is the main French national agency for scientific research. Erwann Loret obtained the GlaxoSmith Kline Drug Discovery and Development Award from an American scientific committee for his contribution to HIV research, the Medail of honor from the Aix Marseille University (AMU) and the French National Institute for Intellectual Properties Award. He is heading the ETRAV lab that is the only lab working on HIV at Marseille. He is member of the Editorial Board of scientific journals and author and co author of 60 scientific publications with a high impact factor and five patents with PCT. His main field of interest is related to the HIV-1 Tat proteins. He is the inventor of the Tat Oyi vaccine and coordinated the EVATAT clinical trial.
https://vaccines-immunization.insightconferences.com/speaker/2017/erwann-loret-aix-marseille-university-france
https://vaccines-immunization.insightconferences.com/abstract/2017/a-reasonable-hope-to-cure-hiv-with-the-tat-oyi-vaccine-results-and-follow-up-of-a-double-blinded-randomized-phase-i-iia-clinical-trial-in-france
ALL RESEARCH OUTPUTS
#18,069,590
of 20,376,777 outputs
OUTPUTS FROM FRONTIERS IN IMMUNOLOGY
#16,368
of 19,094 outputs
OUTPUTS OF SIMILAR AGE
#131,970
of 168,577 outputs
OUTPUTS OF SIMILAR AGE FROM FRONTIERS IN IMMUNOLOGY
#1
of 1 outputs
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 February 2022.
https://frontiers.altmetric.com/details/123533754#score
WH, I like that Answer! Bring it on!!!! :)
Question for you Corpus! Do you see the big bonanza coming anytime soon?
Ronald Kempers, CEO of Mymetics, "We were very
impressed with the professional and thorough work
delivered by Dr. Ruprecht's team, including Dr.
Samir Lakhashe, Staff Scientist at Texas Biomed,
and look forward to understanding the mechanisms
of action of our vaccine.
PDF]Mymetics' HIV vaccine candidate confirms promise in ...
https://medicalxpress.com/pdf379564866.pdf
Samir Lakhashe, Staff Scientist at Texas Biomed, and look forward to understanding the mechanisms of action of our vaccine. This study proves that our HIV vaccine candidate can
Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind ...
https://europepmc.org/article/MED/26023780
May 29, 2015 · Department of Surgery, Duke University, Duke University Medical Center, Durham, North Carolina, United States of America. ... VLPs, liposomes and virosomes (many references are
https://europepmc.org/article/MED/26023780
A virosomal vaccine inducing systemic/mucosal anti-HIV-1 gp41 IgG/IgA had previously protected Chinese-origin rhesus macaques (RMs) against vaginal SHIVSF162P3 challenges. Here, we assessed its efficacy in Indian-origin RMs by intramuscular priming/intranasal boosting (n=12/group). Group K received virosome-P1-peptide alone (harboring the Membrane Proximal External Region), Group L combined virosome-rgp41 plus virosome-P1, and Group M placebo virosomes.
http://121.199.17.194/paper/1496195874951614464
Front. Immunol., 22 February 2022 | https://doi.org/10.3389/fimmu.2022.788619
Cooperation Between Systemic and Mucosal Antibodies Induced by Virosomal Vaccines Targeting HIV-1 Env: Protection of Indian Rhesus Macaques Against Low-Dose Intravaginal SHIV Challenges
Samir K. Lakhashe1‡, Mario Amacker2,3‡, Dinesh Hariraju1,4,5‡, Hemant K. Vyas1, Kyle S. Morrison6, Joshua A. Weiner7, Margaret E. Ackerman6,7, Vicky Roy8, Galit Alter8,9, Guido Ferrari10,11, David C. Montefiori10,11, Georgia D. Tomaras10,11,12,13, Sheetal Sawant10, Nicole L. Yates10, Chris Gast14†, Sylvain Fleury3 and Ruth M. Ruprecht1,4,5*
1Texas Biomedical Research Institute, San Antonio, TX, United States
2Department of Pulmonary Medicine, Bern University Hospital, University of Bern, Bern, Switzerland
3Mymetics SA, Epalinges, Switzerland
4New Iberia Research Center, University of Louisiana at Lafayette, Lafayette, LA, United States
5Department of Biology, University of Louisiana at Lafayette, Lafayette, LA, United States
6Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Hanover, NH, United States
7Thayer School of Engineering, Dartmouth College, Hanover, NH, United States
8Ragon Institute of Massachusetts General Hospital (MGH), Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, United States
9Massachusetts Consortium on Pathogen Readiness, Boston, MA, United States
10Department of Surgery, Duke University, Durham, NC, United States
11Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, United States
12Department of Molecular Genetics and Microbiology, Duke University, Durham, NC, United States
13Department of Immunology, Duke University, Durham, NC, United States
14Fred Hutchinson Cancer Research Center, Seattle, WA, United States
Front. Immunol., 22 February 2022 | https://doi.org/10.3389/fimmu.2022.788619
Cooperation Between Systemic and Mucosal Antibodies Induced by Virosomal Vaccines Targeting HIV-1 Env: Protection of Indian Rhesus Macaques Against Low-Dose Intravaginal SHIV Challenges
Samir K. Lakhashe1‡, Mario Amacker2,3‡, Dinesh Hariraju1,4,5‡, Hemant K. Vyas1, Kyle S. Morrison6, Joshua A. Weiner7, Margaret E. Ackerman6,7, Vicky Roy8, Galit Alter8,9, Guido Ferrari10,11, David C. Montefiori10,11, Georgia D. Tomaras10,11,12,13, Sheetal Sawant10, Nicole L. Yates10, Chris Gast14†, Sylvain Fleury3 and Ruth M. Ruprecht1,4,5*
1Texas Biomedical Research Institute, San Antonio, TX, United States
2Department of Pulmonary Medicine, Bern University Hospital, University of Bern, Bern, Switzerland
3Mymetics SA, Epalinges, Switzerland
4New Iberia Research Center, University of Louisiana at Lafayette, Lafayette, LA, United States
5Department of Biology, University of Louisiana at Lafayette, Lafayette, LA, United States
6Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Hanover, NH, United States
7Thayer School of Engineering, Dartmouth College, Hanover, NH, United States
8Ragon Institute of Massachusetts General Hospital (MGH), Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, United States
9Massachusetts Consortium on Pathogen Readiness, Boston, MA, United States
10Department of Surgery, Duke University, Durham, NC, United States
11Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, United States
12Department of Molecular Genetics and Microbiology, Duke University, Durham, NC, United States
13Department of Immunology, Duke University, Durham, NC, United States
14Fred Hutchinson Cancer Research Center, Seattle, WA, United States
https://www.frontiersin.org/articles/10.3389/fimmu.2022.788619/full
Clinical Trial Vaccine
. 2003 Oct 1;21(27-30):4328-34. doi: 10.1016/s0264-410x(03)00457-2.
Mucosal antibody response induced with a nasal virosome-based influenza vaccine
P Durrer 1, U Glück, C Spyr, A B Lang, R Zurbriggen, C Herzog, R Glück
https://pubmed.ncbi.nlm.nih.gov/14505915/
Building calf immunity with mucosal vaccines
AHA
Sylvain Fleury?
https://www.wisfarmer.com/story/news/2022/02/06/building-calf-immunity-mucosal-vaccines/6686546001/
Lipid-based nanoparticulate delivery systems for HER2 ...
https://www.sciencedirect.com/science/article/pii/S0024320521012819
Volume 291, 15 February 2022, 120294. Review article. ... Virosomes are fusogenic liposomes, which are made by incorporation of proteins from the viral envelope. A variety of viruses have
https://www.sciencedirect.com/science/article/abs/pii/S0024320521012819
Mymetix Corporation
The Swiss Mymetix Corporation (OTC:OTCQB:MYMX) is the third company exploring the nasal route. They share intellectual property with US giant Catalent (NYSE:CTLT) about packing antigenic material in virus-like particles for local application (so-called virosomes). Their nasal COVID-vaccine developed with Baylor College in Texas gave promising preclinical data in animal experiments. It might be of interest that they have the support of the Bill Gates foundation and of billionaire Ernesto Bertarelli.
https://lukasfierz.blogspot.com/2021/04/vaxart-in-competitive-race-for-non.html
Global Neoantigen Cancer Vaccine Markets, Competition, Forecast & Opportunities, 2026 – ResearchAndMarkets.com
Global Neoantigen Cancer Vaccine Market, By Delivery Mechanism:
Liposomes
Virosomes
Gene gun
Electroporation
Others
https://www.financialbuzz.com/global-neoantigen-cancer-vaccine-markets-competition-forecast-opportunities-2026-researchandmarkets-com/